Search results for "anticoagulation"

showing 10 items of 45 documents

Inadequate oral anticoagulation with warfarin in women with cerebrovascular event and history of atrial fibrillation: the FibStroke study

2021

Abstract Background Women with atrial fibrillation (AF) may be treated less actively with oral anticoagulation (OAC) than men. Patients and methods We assessed sex differences in the implementation of stroke risk stratification with CHADS2 and CHA2DS2-VASc scores and reasons not to use OAC in 1747 AF patients suffering their first cerebrovascular event after the AF diagnosis. Results Women were older and had more often a high stroke risk (CHADS2/CHA2DS2-VASc ≥2) than men (p < .001). On admission, 46.4% of women and 48.2% of men were on OAC with no sex difference (p = .437). However, of patients without OAC, 74.4% of women and 49.5% of men should have been on OAC based on CHADS2/CHA2DS2-VASc…

Malemedicine.medical_specialtylääkemääräyksetsukupuolierotAtrial fibrillation (AF)oral anticoagulation (OAC)030204 cardiovascular system & hematologyRisk AssessmentArticleStroke riskCHADS203 medical and health sciencesSex Factors0302 clinical medicineInternal medicineAtrial Fibrillationparasitic diseasesmedicinesexHumanscardiovascular diseases030212 general & internal medicineOral anticoagulationEvent (probability theory)business.industryWarfarinAnticoagulantsAtrial fibrillationGeneral Medicineeteisvärinämedicine.diseasehyytymisenestohoitoStrokeCerebrovascular DisordersCHA2DS2-VAScatrial fibrillation (AF)sydän- ja verisuonitauditCardiologyFemaleWarfarinbusinessResearch Articlemedicine.drugAnnals of Medicine
researchProduct

Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH…

2018

During the last few years, the number of patients receiving anticoagulant and antiplatelet therapy has increased worldwide. Since this is a chronic treatment, patients receiving it can be expected to need some kind of surgery or intervention during their lifetime that may require treatment discontinuation. The decision to withdraw antithrombotic therapy depends on the patient's thrombotic risk versus hemorrhagic risk. Assessment of both factors will show the precise management of anticoagulant and antiplatelet therapy in these scenarios. The aim of this consensus document, coordinated by the Cardiovascular Thrombosis Working Group of the Spanish Society of Cardiology, and endorsed by most o…

Malemedicine.medical_specialtymedicine.drug_classHemorrhage030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRisk FactorsThromboembolismIntervention (counseling)Preoperative CareAntithromboticmedicineHumans030212 general & internal medicineIntensive care medicineAgedAged 80 and overThrombotic riskIntraoperative CareDrug Substitutionbusiness.industryAnticoagulantAnticoagulantsGeneral MedicinePerioperativemedicine.diseaseThrombosisDiscontinuationConventional PCIFemaleAntiagregación Anticoagulación Anticoagulation Antiplatelet Antithrombotic Antitrombótico Cirugía SurgerybusinessPlatelet Aggregation InhibitorsRevista Española de Cardiología (English Edition)
researchProduct

Hemorrhage in patients under oral anticoagulation for atrial fibrillation. The other side of the coin

2019

Abstract Introduction and objectives Oral anticoagulation therapy is prescribed to most patients with atrial fibrillation. The main limitation of anticoagulant treatment is the occurrence of bleeding episodes. We sought to assess the type of hemorrhages and mortality in patients anticoagulated for nonvalvular atrial fibrillation. Methods Observational retrospective study analyzing 2 081 138 hospitalization reports from 2014 corresponding to 151 hospitals of the Spanish National Health System. Patients were selected with the diagnosis of hemorrhage, nonvalvular atrial fibrillation, and oral anticoagulation. Results A total of 5783 hospitalizations were analyzed. Most hemorrhages were digesti…

National healthmedicine.medical_specialtyBleeding episodeseducation.field_of_studybusiness.industryPopulationRetrospective cohort studyAtrial fibrillationmedicine.diseaseAnticoagulant therapyInternal medicinemedicineIn patientCardiology and Cardiovascular MedicineeducationbusinessOral anticoagulationREC: CardioClinics
researchProduct

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ER…

2020

Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

ORAL ANTICOAGULANT-THERAPYdiagnosis[SDV]Life Sciences [q-bio]Medizin030204 cardiovascular system & hematologyEmbolectomyGuidelineRECURRENT VENOUS THROMBOEMBOLISM0302 clinical medicinePregnancyDaily practiceDiagnosisPulmonary medicineVenous thrombosisPulmonary MedicineThrombolytic TherapyDEEP-VEIN THROMBOSISDisease management (health)Societies MedicalComputingMilieux_MISCELLANEOUShealth care economics and organizationsRisk assessmentddc:616RIGHT-VENTRICULAR DYSFUNCTIONDisease ManagementShockMOLECULAR-WEIGHT HEPARINThrombolysishumanities3. Good healthPulmonary embolismEuropeAnticoagulation; Biomarkers; Diagnosis; Dyspnoea; Echocardiography; Embolectomy; Guidelines; Heart failure; Pregnancy; Pulmonary embolism; Right ventricle; Risk assessment; Shock; Thrombolysis; Treatment; Venous thromboembolism; Venous thrombosismedicine.veinEchocardiographyAcute DiseaseRight ventricleMedical emergencyCardiology and Cardiovascular MedicineRisk assessmentguidelines; pulmonary embolism; venous thrombosis; shock dyspnoea; heart failure: right ventricle: diagnosis; risk assessment: echocardiography; biomarkers; treatment; anticoagulation; thrombolysis; pregnancy; venous thromboembolism; embolectomyDiagnosiVenous thromboembolismthrombolysiseducationCardiologyMEDLINEThrombolysiHeart failure610 Medicine & healthGuidelinesInferior vena cava2705 Cardiology and Cardiovascular MedicineEXTRACORPOREAL MEMBRANE-OXYGENATION03 medical and health sciencesAnticoagulationMedicalDyspnoeamedicineHumansRIGHT HEART THROMBIVENTILATION-PERFUSION SCINTIGRAPHYshock dyspnoeaHealth professionalsbusiness.industryINFERIOR VENA-CAVA10031 Clinic for Angiologyheart failure: right ventricle: diagnosisPulmonary embolismAnticoagulantsbiomarkersrisk assessment: echocardiography030229 sport sciencesBiomarkermedicine.diseaseTreatmentINHALED NITRIC-OXIDESocietiesbusinessBiomarkers
researchProduct

Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Mali…

2021

Immune checkpoint inhibitors (ICI) significantly improved the prognosis of advanced melanoma patients. However, many patients do not derive long-term benefit from ICI therapy due to primary and acquired resistance. In this regard, it has been shown that coagulation factors contribute to cancer immune evasion and might therefore promote resistance to ICI. In particular, recent observations in murine systems demonstrated that myeloid-derived factor Xa (FXa) impedes anti-tumor immunity in the tumor microenvironment and that the oral FXa inhibitor (FXa-i) rivaroxaban synergizes with ICI. The synergistic effect of FXa inhibitors with clinical ICI therapy is unknown. We performed a retrospective …

Oncologyadvanced melanomaCancer Researchmedicine.medical_specialtymedicine.drug_mechanism_of_actionmedicine.medical_treatmentFactor Xa Inhibitorfactor Xa inhibitorsanti-tumor immunityArticleimmune checkpoint inhibitorsInternal medicinemedicineProgression-free survivalanticoagulationRC254-282thromboembolic eventsRivaroxabanbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerRetrospective cohort studyImmunotherapymedicine.diseaseOncologyConcomitantimmunotherapythromboprophylaxisbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugCohort studyCancers
researchProduct

PHQ-2 and GAD-2 scores predict mortality in patients undergoing oral anticoagulation

2015

Psychiatry and Mental healthClinical Psychologymedicine.medical_specialtybusiness.industryInternal medicinemedicineIn patientbusinessOral anticoagulationJournal of Psychosomatic Research
researchProduct

A review of venous thromboembolism in COVID‐19: A clinical perspective

2021

Abstract Coronavirus disease‐19 (COVID‐19) started in Wuhan, China in December 2019 and spread to all around the world in a short period of time. Hospitalized patients with COVID‐19 mostly could suffer from an abnormal coagulation activation risk with increased venous thrombosis events and a poor clinical course. The reported incidence rates of thrombotic complications in hospitalized COVID‐19 patients vary between 2.6 and 85% (both in non‐critically ill and critically ill patients). The risk of venous thromboembolism is not known in non‐hospitalized patients with COVID‐19. There are numerous studies and guidelines for administration of thromboprophylaxis for COVID‐19 cases. All hospitalize…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Hospitalized patientsCritical IllnessGlobal Health03 medical and health sciences0302 clinical medicineCOVID‐19medicineHumansImmunology and AllergyGenetics(clinical)030212 general & internal medicineanticoagulationIntensive care medicinePandemicsContraindicationGenetics (clinical)Critical perspectiveSARS-CoV-2business.industryCritically illIncidenceCOVID-19Venous ThromboembolismOriginal Articlesmedicine.diseasemortalityLMWHVenous thrombosis030228 respiratory systemOriginal Articlevenous thrombosisbusinessVenous thromboembolismThrombotic complicationThe Clinical Respiratory Journal
researchProduct

Immediate bleeding complications in dental implants: A systematic review

2014

Objective: A review is made of the immediate or immediate postoperative bleeding complications in dental implants, with a view to identifying the areas of greatest bleeding risk, the causes of bleeding, the length of the implants associated with bleeding, the most frequently implicated blood vessels, and the treatments used to resolve these complications. Material and Methods: A Medline (PubMed) and Embase search was made of articles on immediate bleeding complications in dental implants published in English up until May 2014. Inclusion criteria: studies in humans subjects with severe bleeding immediately secondary to implant placement, which reported the time until the hemorrhage, the impl…

Severe bleedingmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentPerforation (oil well)DentistryOdontologíaReviewPostoperative HemorrhageAnticoagulation TreatmentMandibular caninemedicineIntubationHumansGeneral DentistryDental Implantsbusiness.industry:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludSurgeryImplant placementOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryImplantOral SurgerybusinessAirwayMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

Position paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL

2018

Although direct oral anticoagulants (DOAC) do not require dose-adjustment on the basis of laboratory test results, the measurement of their anticoagulant effect is useful in special situations. This position paper issued by the Italian Scientific Societies that are mainly involved in the management of patients on DOAC is aimed at providing guidance to care-givers on which tests should be used and the situations in which testing is useful. The guidance is based on the data from the literature so far available and/or on consensus among experts.

Societies ScientificOralConsensusDOACAnticoagulantAnticoagulation; Consensus; DOAC; Thrombosis; Administration Oral; Anticoagulants; Drug Monitoring; Humans; Italy; Societies Scientific; Immunology and Allergy; HematologyAdministration OralAnticoagulantsConsensuThrombosisScientificHematologyLong-Term CareAnticoagulationSettore BIO/12 - Biochimica Clinica E Biologia Molecolare ClinicaItalyThrombosiAdministrationHumansImmunology and AllergyPosition PaperDOAC; anticoagulation; thrombosis; consensusDrug MonitoringSocietiesHuman
researchProduct

2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism

2014

ACS : acute coronary syndrome AMPLIFY : Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-line Therapy aPTT : activated partial thromboplastin time b.i.d. : bis in diem (twice daily) b.p.m. : beats per minute BNP : brain natriuretic peptide BP : blood pressure CI : confidence interval CO : cardiac output COPD : chronic obstructive pulmonary disease CPG : Committee for Practice Guidelines CRNM : clinically relevant non-major CT : computed tomographic/tomogram CTEPH : chronic thromboembolic pulmonary hypertension CUS : compression venous ultrasonography DSA : digital subtraction angiography DVT : deep vein thrombosis ELISA : enzyme-linked immunosorben…

Vitamin KVasodilator AgentsAdministration OralChest pain; Diagnosis; Dyspnoea; Guidelines; Heart failure; Hypotension; Pulmonary embolism; Shock; Thrombolysis; Treatment-Anticoagulation; Venousthrombosis; Administration Oral; Algorithms; Anticoagulants; Biomarkers; Chronic Disease; Clinical Laboratory Techniques; Diagnostic Imaging; Embolectomy; Endovascular Procedures; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Heart Failure; Home Care Services; Humans; Hypertension Pulmonary; Long-Term Care; Neoplasms; Pregnancy; Pregnancy Complications Cardiovascular; Prognosis; Pulmonary Embolism; Risk Factors; Vasoconstrictor Agents; Vasodilator Agents; Vitamin K; Cardiology and Cardiovascular MedicineEmbolectomyCardiovascularChest painPregnancyRisk FactorsNeoplasmsDiagnosisVasoconstrictor AgentsSocieties MedicalEndovascular ProceduresShockGeneral MedicinePulmonaryPrognosisThrombosisThrombolysisHome Care ServicesPulmonary embolismEuropeVenous thrombosismedicine.veinPractice Guidelines as TopicAdministrationHypertensionCardiologyApixabanFemaleRadiologyHypotensionCardiology and Cardiovascular MedicineAlgorithmsmedicine.drugOralDiagnostic Imagingmedicine.medical_specialtypumonary hypertensionmedicine.drug_classHypertension PulmonaryPregnancy Complications CardiovascularCardiologyMEDLINELow molecular weight heparin610 Medicine & healthHeart failureGuidelinesInferior vena cavaFibrin Fibrinogen Degradation ProductsText miningFibrinolytic AgentsInternal medicineDyspnoeamedicineHumansIntensive care medicinebusiness.industryClinical Laboratory TechniquesPulmonary embolismAnticoagulantsTreatment-Anticoagulationmedicine.diseasePulmonary hypertensionLong-Term CarePregnancy ComplicationsVenousthrombosisHeart failureChronic DiseasebusinessBiomarkers
researchProduct